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GVHD prophylaxis consisted of CYA starting day -1 and MTX on days þ 1 and þ 3. To shorten aplasia, MTX was not given on days þ 6 and þ 11, and G-CSF was started on day þ 8. Instead, prednisolone was administered according to the Stanford scheme and tapered by day þ 27.
On day þ 20, the patient was still positive for pandemic H1N1, and a serum galactomannan assay for aspergillus demonstrated a positive result. Fluconazole was replaced by voriconazole, and substitution with i.v. Igs was initiated.
A second chest CT scan showed streaky consolidation and fibrosis involving subpleural and peribronchial areas, but no typical signs of invasive pulmonary aspergillosis (Figure 1b) . At that time, the patient developed severe respiratory distress and required supplemental oxygen. Intermittent non-invasive ventilation was initiated.
A triple combination of oseltamivir 150 mg twice daily, amantadin 75 mg thrice daily and ribavirin 200 mg twice daily was started. Because of suspected oseltamivir resistance and prolonged viral shedding, viral resistance was tested by genotyping and IC50 phenotyping from nasal and pharyngeal areas, before triple therapy. Resistance testing revealed two virus subpopulations, one susceptible to oseltamivir, the other resistant to oseltamivir (Figure 2a ). There was a resistance to oseltamivir based on a known mutation that results in a histidine-to-tyrosine substitution at position 274 (H274Y). Both the subpopulations were susceptible to zanamivir.
In accordance with the data of the World Health Organization, up to February 2010, a total of 225 oseltamivir-resistant H1N1-09 cases had been reported worldwide. All these cases were based on the H274Y mutation, conferring resistance to oseltamivir but not to zanamivir.
2 Therefore, zanamivir represents the therapeutic option for patients infected with the H274Y mutation of H1N1-09 virus.
After 2 weeks, the triple therapy was stopped, as the oseltamivir-resistant virus population increased ( Figure 2b ) and, finally, only oseltamivir-resistant virus was detectable ( Figure 2c ). The follow-up CT scan showed worsening fibrosis (Figure 1c) . At that time, we initiated i.v. zanamivir, supplied within a GlaxoSmithKline compassionate use program, and topical zanamivir.
Zanamivir was administered twice daily 600 mg i.v. and at the same time as an aerosilized formula twice daily 10 mg. Ten days later, virus RNA was no longer detectable. Virus clearance was confirmed in subsequent tests. The final chest CT scan revealed post-pneumonia fibrosis (Figure 1d) .
The final pulmonary function test showed a moderate restrictive ventilation disorder and a moderate diffusion disturbance.
Several aspects of this case report deserve attention. First, despite accommodation in single rooms with HEPAfiltered air supply, the use of face masks and frequent hand disinfections, the patient acquired H1N1 infection during the pandemic peak in Germany. Despite investigative efforts, the route of infection could not be clarified. It cannot be excluded that the patient has been infected by a medical staff with asymptomatic disease. The most effective measure to protect patients from influenza during a pandemia is by active immunization of medical staff. Personal rights of the medical staff, however, preclude systematic testing for H1N1 or reporting of the vaccination status. Especially, when asymptomatic or mild infections occur during a pandemia-as it was the case in Germanymedical staff themselves become an important vector for infection.
Drug resistance is a potential concern for all antiviral agents. Oseltamivir resistance based on H274Y mutation occurring in the NA enzyme was first detected in experimental influenza A/Texas H1N1-infected volunteers under treatment with oseltamivir. 3 This variant has been shown to have substantially reduced infectivity and pathogenicity, both in vivo and in vitro. 4 On the basis of the data from both in vitro and experimental animal models indicating that anti-influenza agents with differing mechanisms of antiviral action act synergistically, we initiated a triple combination of amantadine, ribavarin and oseltamivir. 5, 6 This empirical approach failed to overcome the resistance. The rational administration of zanamivir, guided by testing for specific mutations of the virus, however, succeeded. 
Letter to the Editor
To date, isolation of H1N1 mutants resistant to zanamivir in vivo has not been reported.
However, a mutant influenza B virus with an R152K NA mutation was isolated from a child after BMT, after prolonged treatment with zanamivir. 7 The pandemic H1N1-09 virus carrying the H274Y mutation is susceptible to zanamivir. If this mutation is detected, zanamivir should be considered the therapy of choice.
Long-term shedding of influenza viruses in immunocompromised patients illustrates the need for careful monitoring of virus isolates for potential drug resistance. This group of patients is at risk of community respiratory viruses associated with substantial morbidity and mortality.
As illustrated by this case report, pandemic H1N1 pneumonia represents a life-threatening problem, even for patients in a highly protective environment, through vectors with no or only mild symptoms. Prolonged viral persistence was associated with severe lung injury. Careful monitoring of viral resistance in patients with prolonged shedding may help to direct effective antiviral treatment. 
